Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London

Claus Thestrup

Claus Thestrup

CEO, HCA Capital Sweden

Idogen participated in the scientific conference ISTH 2022 Congress organized by the International Society on Thrombosis and Hemostasis (ISTH) on 9–13 July in London. This international conference, which is aimed at researchers, clinicians and life science companies, is this year’s most important meeting in the field of coagulation and bleeding diseases.

Idogen met with the company’s scientific advisers and representatives from all the clinical centers that will conduct the company’s clinical phase I/IIa study for IDO 8 during the conference. The discussions touched upon both new scientific advances in the field and the ongoing development of the company’s cell therapy, IDO 8. Idogen was represented on site by the company’s CEO Anders Karlsson and Hanjing Xie, Idogen’s Chief Medical Officer.

Idogen develops tolerogenic cell therapies where the goal is to prevent an unwanted activation of the immune system. For patients with hemophilia A, one third of patients develop neutralizing antibodies to the standard treatment and render it inactive. To prevent the body’s immune system from attacking such biological drugs, Idogen has developed a patient-specific cell therapy with the intention of creating tolerance for the patient’s treatment. The goal is that the patient can thus continue with his vital treatment.

Disclaimer: HC Andersen Capital receives payment from Idogen for a DigitalIR/Corporate Visibility agreement.